We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pevonedistat is currently in phase 3 studies as a first-line treatment for patients with HR-MDS and higher-risk chronic myelomonocytic leukemia. Read More
Pfizer confirmed that it plans to charge $19.50 per dose of its COVID-19 vaccine in the U.S., with a total cost of about $40 for a two-dose regimen. Read More
Farxiga was approved by the FDA in May for reducing the risk of hospitalization and cardiovascular death in adults with heart failure when their left ventricle is not pumping normally. Read More